



INDIA GLYCOLS LIMITED



Plot No. 2-B, Sector - 126, NOIDA-201304, Distt. Gautam Budh Nagar (Uttar Pradesh), Tel. : +91 (120) 6860000, 3090100, 3090200
Fax : +91 (120) 3090111, 3090211, E-mail : iglho@indiaglycols.com, Website : www.indiaglycols.com

IGL/SE/R30/2025-26/01

25th April, 2025

The Manager (Listing)
BSE Limited
1st Floor, New Trading Ring,
Rotunda Building, P.J. Towers,
Dalal Street,
Mumbai- 400 001

The Manager (Listing)
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (East)
Mumbai – 400 051

Scrip Code: 500201

Symbol: INDIAGLYCO

Dear Sirs,

Sub: Disclosure under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”) – Intimation for the receipt of Establishment Inspection Report (EIR) from US Food and Drug Administration (USFDA) for Nutraceuticals Products and dietary supplements ingredients at Dehradun Plant.

Pursuant to Regulation 30 of the SEBI Listing Regulations, we wish to inform you that the Company has received the **Establishment Inspection Report (EIR) with no observation from US Food and Drug Administration (USFDA)** on 24th April, 2025 for the Company's nutraceutical products and dietary supplements ingredients at Dehradun Plant.

The receipt of EIR underscores the Company's commitment to adhering to global quality standards and paves the way for access to the premium U.S. market, along with other highly regulated global markets.

This is for your information and record.

Thanking you,

Yours truly,

For **India Glycols Limited**

Ankur Jain
Head (Legal) & Company Secretary